Counterpoint: Biotech needs more than DTC as usual
Article Abstract:
A pharmaceutical marketing expert has given his views on biotech companies adopting direct-to-consumer (DTC) advertising to promote their products just like pharmaceutical companies. The DTC format is unsuitable for informing consumers about the benefits/risks of more complex biologics and targeted therapies and it cannot be easily targeted to segmented audiences.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
From oligos to Oprah - the consumer and biotech
Article Abstract:
The impact of product advertising and corporate brand image-making on the biotechnology industry is discussed. Biotech companies should understand that there no other way to reach the public and make them aware about the progress made in the laboratory and in the clinic to treat disease than through the media with direct-to-consumer marketing.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Protein biopesticide may be next wave in pest control
Article Abstract:
The U.S. Food and Drug Administrationc approved the use of Messenger, a protein-based pesticide manufactured by Eden Bioscience, for use against pests in agricultural crops.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Contribution of women to U.S. marketing thought: the consumers' perspective, 1900-1940. Developing new rules for new markets
- Abstracts: Over-reaction by security market analysts: the impact of broker status and firm size. Alternative solutions to underinvestment, under equity and credit rationing
- Abstracts: White House warrior: arm for web battle. Virtual risk management. Surviving and thriving
- Abstracts: Don't hide bad news, NIRI conference told. New CEO of NIRI revamps staff. Fisher, Krauss join Streampipe
- Abstracts: Money and credit in liquidity provision. A critique on the theory of financial intermediation. Value at risk models for Dutch bond portfolios